Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With COPD

Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With Chronic Obstructive Pulmonary Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02903043

Enrollment

100

Registered

2016-09-16

Start date

2013-02-28

Completion date

2018-02-28

Last updated

2017-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

MicroRNAs, Angiogenesis, Skeletal muscle, COPD

Brief summary

Limb muscle dysfunction, characterized by loss of capillaries, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality. One prevailing hypothesis stipulates that modification in the expression of miR-204 leads to change the regulation of angiogenesis in vastus lateralis of patients with COPD when compared to controls.

Detailed description

The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle angiogenesis. Mild to severe COPD patients and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins and microRNAs of signaling intramuscular pathways involved in angiogenesis will be measured in the quadriceps.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* COPD (FEV1/FVC \< 0.70) * Healthy subjects: no evidence of airways obstruction (FEV1/FVC \> 0.70 and FEV1 \> 0.80 predicted) * Smoking history \> 10 pack-years * Ex-smoker \>6 months

Exclusion criteria

* Chronic hypoxemia and/or hypercapnia (PaO2 \< 60 mmHg or SpO2 \< 88% at rest and/or PaCO2 \> 45 mmHg) * Recent exacerbation or oral corticosteroids (\< 2 months) * Recent cancer (\< 3 years) * Diabetes * Myopathy, neuromuscular, neurological or articular diseases * Kidney disease * Other respiratory diseases * Unstable cardiac disease * Physical activity score \> 9 in the Voorips questionnaire * BMI \> 30

Design outcomes

Primary

Measure	Time frame	Description
miR-204 in limb muscles in patients with COPD	At baseline (COPD patients in a stable state of the disease)	i)To measure miR-204 level in the quadriceps of patients with COPD in comparison to controls. ii) To study possible involvement of miR-204 on pathways regulating angiogenesis and on muscle microcirculation in these individuals.

Secondary

Measure	Time frame	Description
microRNAs in limb muscles of patients with COPD	At baseline (COPD patients in a stable state of the disease)	i) To measure microRNAs levels in the quadriceps of patients with COPD in comparison to controls. ii) To study possible involvement of these microRNAs on pathways regulating myogenesis, angiogenesis and on muscle microcirculation in these individuals.

Countries

Canada

Outcome results